Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 05/12/2025 GMT			5-day change	1st Jan Change
121.22 ^USD	-1.14%		-3.67%	+31.23%

12-03	Soleno Therapeutics, Inc. Announces Demise of William G. Harris, Member of Board of Directors and Audit Committee Changes	CI
12-03	Gilead Sciences, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10:50 AM

Highlights

First Venture Sweden Private says Sprint Bioscience sells cancer program TREX1 to Gilead Sciences	11-24	RE
Sprint Bioscience Surges After Selling Cancer Program to Gilead Sciences	11-24	FW
Sprint Bioscience Enters Deal to Sell TREX1 Cancer Program	11-24	MT
Major deals involving U.S. drugmakers and biotechs over the past decade	11-20	RE
Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial	11-19	RE
Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa	11-18	CI
Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 Trial	11-13	CI
MacroGenics Q3 revenue declines, secures $75 mln in partnerships	11-12	RE
Assembly Biosciences Q3 net loss narrows, raises $175 mln	11-10	RE
ADC Therapeutics Q3 net income beats analyst expectations	11-10	RE
Clinical-stage cancer immunotherapy firm Compugen's Q3 net loss widens	11-10	RE
Gilead in October reached settlement with a tax authority related to a prior year legal entity restructuring - filing	11-07	RE
Sector Update: Health Care Stocks Ease Late Afternoon	11-07	MT
Gilead Sciences, Inc. Provides Update on Phase 3 ASCENT-07 Study	11-07	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	11-07	MT
Gilead's Livdelzi Demonstrates Sustained Efficacy in Primary Biliary Cholangitis, Offering Alkaline Phosphatase Reduction, Itch Relief and Potential to Slow Disease Progression	11-07	CI
Immuthera and Its Wholly Owned Subsidiary of Poltreg S.A Appoints Adrian Bot to Its Board of Directors	11-07	CI
Prime Medicine Q3 net loss narrows	11-07	RE
Moderna trims annual expenses outlook on lower production costs, R&D cuts	11-06	RE
Tango Therapeutics reports Q3 net income, revenue jumps	11-04	RE
Galapagos NV Announces Board Changes, Effective November 1, 2025	10-31	CI
Gilead posts higher profit on demand for HIV drugs, but overall sales dip	10-30	RE
Gilead Sciences Lifts Outlook with Higher 3Q Sales, Profit	10-30	DJ
Gilead Sciences Q3 Non-GAAP Earnings, Revenue Rise; 2025 Guidance Adjusted	10-30	MT
(GILD) Gilead Updates Full Year 2025 Product Sales Outlook Range To $28.40 Billion - $28.70 Billion, vs. FactSet Est $28.71 Billion	10-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Time To Grow PFL Fanbase, Revenue: CEO John Martin

July 11, 2025 at 09:09 am